Drug intelligence / Profile preview

YZ-001

Development stage: Unknown
Lead developer: Guangdong Yinzhu Pharmaceutical Technology
Modality: Small Molecules
Administration: Oral

Overview

YZ-001 is a small molecule inhibitor of the NF-κB signaling pathway, currently under development by Guangdong Yinzhu Pharmaceutical Technology. It is primarily being investigated in Phase 3 clinical trials for the treatment of metastatic non-small cell lung cancer (NSCLC) in patients with bone metastases, administered in combination with platinum-based doublet chemotherapy. NF-κB is a key transcription factor that regulates genes involved in inflammation, cell survival, and bone resorption; its inhibition by YZ-001 is intended to disrupt the "vicious cycle" of bone metastasis and enhance the anti-tumor activity of conventional chemotherapy.

Other names: YZ-001YZ001YZ 001

Targets

NF-κB

Beyond the preview

Go deeper on YZ-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YZ-001.

Explore the full profile